##
||||Pages|
|---|---|---|---|
|Reference and Administrative||Information||
|Trustees'
Report|||2-4|
|Independent
examiner's|report|||
|Statement
of Financial|Activities|||
|Balance Sheet||||
|Notes to the Financial Statements|||8-14|
|||Reference and Administrative|Reference and Administrative|Information|
|---|---|---|---|---|
|||for the year ended 5April||2023|
|Charity Reference:||1003899|||
|Trustees:||Mark Greaves|||
|||Michael Tyler (Chairman)|||
|||Michael Constant|||
|||James Naylor|||
|||Adam Renton|||
|||Mark Braganza|||
|||Jon Pleat|||
|Address:||Plastic Surgery J|Corridor||
|||Stoke Mandeville|Hospital||
|||Mandeville
Road|||
|||Aylesbury|||
|||HP21 8AL|||
|Independent|Examiner:|Wenn Townsend|||
|||30StGiles|||
|||Oxford|||
|||Oxfordshire|||
|||OX1 3LE|||
|Solicitors:||Horwood 8 James|LLP||
|||7Temple Square|||
|||Aylesbury|||
|||Bucking
ham shire|||
|||HP20 2QB|||
|Bankers:||HSBC Bank pic|||
|||2 Walton Road|||
|||Aylesbury|||
|||Bucking ham shire|||
|||HP21 7SS|||
|Investment|managers:|M 8 G Charities|||
|||PO Box9038|||
|||Chelmsford|||
|||Essex|||
|||CM99 2XF|||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||Restore - Burn and Wound Resear|Restore - Burn and Wound Resear|Restore - Burn and Wound Resear|
|---|---|---|---|---|---|---|---|
||||||Statement ofFinancial Activides|||
||||||For|the year ended|5 April 2023|
|||||Note|Unrestricted|Restricted|Total|
||||||funds|funds|2023|
||||||E|E|E|
|Income:||||||||
|Voluntary
income|||||2,588||2,588|
|Activities for raising funds||||||60,296|60,296|
|Total income|||||2,588|60,296|62,884|
|Expenditure:-||||||||
|Costs of raising
voluntary|||income|5|1,295||1,295|
|Charitable
expenditure:||Burns Research||6|28,257|23,123|51,380|
|Totalexpenditure|||||29,552|23,123|52,675|
|Net (expenditure)flncome|||||(26,964)|37,173|10,209|
|Net (expenditure)/income||before gains on||||||
|investments|||||(26,964)|37,173|10,209|
|Unrealised
gains/(losses)
Realised gains on disposal||on|investments|9
9|(1,132)
(411)||(1,132)
(411)|
||||||(28,507)|37,173|8,666|
|Transfers
between
funds||||||||
||||||(28,507)|37,173|8,666|
|Fund balance brought|forward||||87,966|61,153|149,119|
|Fund balance carried forward|||||59,459|98,326|157,785|
|Unrestricted|Restricted|Endowment|Total|
|---|---|---|---|
|funds|funds|funds|2022|
|E||E|E|
|3,982|||3,982|
||27,000||27,000|
|3,982|27,000||30,982|
|1,218|||1,218|
|30,832|587||31,419|
|32,050|587||32,637|
|(28,068)|26,413||(1,655)|
|(28,068)|26,413||(1,655)|
|||10,926|10,926|
|(28,068)|26,413|10,926|9,271|
|104,834||(104,834)||
|76,766|26,413|(93,908)|9,271|
|11,200|34,740|93,908|139,848|
|87,966|61,153||149,119|
##
||||Note||2023|||2022|
|---|---|---|---|---|---|---|---|---|
|Fixed assets|||||||||
|Investments
Tangible assets|||9
10|||71,791
2,157||103,333
2,876|
|Current assets||||||73,948||106,209|
|Debtors
HSBC —community
Barclays account|account|||443
85,879|||929
45,469
174||
|||||86,322|||46,572||
|Current liabilities|||||||||
|Creditors|||12|(2,485)|||(3,662)||
|Net current assets||||||83,837||42,910|
|Net assets||||||157,785||149,119|
|Funds|||||||||
|Expendabie
endowment||funds|||||||
|Unrestricted
funds|—|General|13|||59,459|||
|||Designated|13|||||87,966|
|Restricted funds|||14|||98,326||61,153|
|||||||157,785||149,119|
##
##
##
##
##
##
##
##
|Voluntary||income|||||
|---|---|---|---|---|---|---|
||||Unrestricted|Restricted|Total|Total|
||||||2023|2022|
||||||E||
|Donations|and legacies||2,588||2,588|2,622|
|Sponsorship||Income||60,296|60,296|1,360|
||||2,588|60,296|62,884|3,982|
##
##
##
|||||Unrestricted|Restricted|Total|Total|
|---|---|---|---|---|---|---|---|
|||||||2023|2022|
||Medical Research Council||||60296|60296|27000|
||||||60,296|60,296|27,000|
|5.|Costs of raising funds|||||||
|||||Unrestricted|Restricted|Total|Total|
|||||||2023|2022|
||||||||E|
||Advertising|and publicity||432||432|432|
||Support costs (note||7)|204||204|330|
||Fundraising|||||||
||Office expenses|||659||659|456|
|||||1,295||1,295|1,218|
|6.|Charitable|expenditure||||||
|||||||Total|Total|
|||||Unrestricted|Restricted|2023|2022f|
||Fellows' salaries||||22,967|22,967|579|
||Director of|Research||22,000||22,000|24,000|
||Support costs (note||7)|2,354|6|2,360|3,572|
||Research,|equipment|and travel||150|150||
||Prizes awarded|||800||800|500|
||Governance|costs (note 7)||3,103||3,103|2,768|
||Sponsorship|Refund||||||
|||||28,257|23,123|51,380|31,419|
##
##
##
##
||Costs ofgenerating|Costs ofgenerating|Charitable|Governance|Total|Total|
|---|---|---|---|---|---|---|
|||Funds|expenditure||2023
E|2022
f|
|Depreciation||72|575|72|719|959|
|Treasurer
salary||100|800|100|1,000|1,841|
|Secretarial
salary and|expenses|32|260|33|325|500|
|Auditor's
remuneration||||2,898|2,899|2,438|
|Insurance|||635||635|617|
|Legal Fees||||||300|
|Bank charges|||90||90|15|
||||2,360|3,103|5,668|6,670|
##
##
|Investments|||||
|---|---|---|---|---|
||||2023|2022|
|Investments
are stated at fair value and movements||are:|||
|At 6 April 2022|||103,333|92,407|
|Disposal Proceeds|||(29,999)||
|Gain on disposal|||(1,132)||
|Increase/(Decrease)|in market value||(411)|10,926|
|At 5 April 2023|||71,791|103,333|
##
##
|10.|Tangible fixed assets||||
|---|---|---|---|---|
|||||Computer and|
||||other equipment||
||Cost:||||
||At 6 April 2022 and at|5 April 2023||84,470|
||Depreciation:||||
||At 6 April 2022|||81,594|
||Charge for year|||719|
||At 5 April 2023|||82,313|
||Net book value:||||
||At 5 April 2023|||2,157|
||At 5 April 2022|||2,876|
|11.|Debtors||||
||||2023f|2022
f.|
||Prepayments||443|929|
||||443|929|
|12.|Creditors||||
||Audit and accountancy|accrued|2,160|2,621|
||Other accruals||325|1,041|
||||2,485|3,662|
##
##
|||At|||Gain on||At|
|---|---|---|---|---|---|---|---|
|||6April 2022|Income|Expenditure|investment|Transfer|5 April 2023|
|||F||||||
|General
fund
Designated
funds||87,966|2,588|(29,553)|(1,542)|87,966
(87,966)|59,459|
|Total unrestricted|funds|87,966|2,588|(29,553)|(1,542)||59,459|
|||At|||Gain on||At|
|||6April 2021|Income
F|Expenditure
f|investment|Transfer
F|5 April 2022|
|General
fund|||3,982|(31,550)||27,568||
|Designated
funds||11,200||(500)||77,266|87,966|
|Total unrestricted|funds|11,200|3,982|(32,050)||104,834|87,966|
##
##
|Restricted funds|||||
|---|---|---|---|---|
||BEST"|Immunomodulation|Medical||
|Current year|project|project|equipment
F.|Totalf|
|Balance at 6 April 2022|13,296|47,835|22|61,153|
|Income|33,296|27,000||60,296|
|Expenditure|(150)|(22,967)|(6)|(23,123)|
|Balance at 5 April 2023|46,442|51,868|16|98,326|
||BEST*|Immunomodulation|Medical||
|Prior year|project|project|equipment|Total|
|||F|||
|Balance at 6 April 2021|13,296|21,414|30|34,740|
|Income||27,000||27,000|
|Expenditure||(579)|(8)|(587)|
|Balance at 5 April 2022|13,296|47,835|22|61,153|
##
##
##
|Division|of net assets between funds||||
|---|---|---|---|---|
|Current|year||||
|||Unrestricted|Restricted||
|||funds|funds|Total|
|Fixed assets|||||
|Tangible|fixed assets|2,141|16|2,157|
|Investments||71,791||71,791|
|||73,932|16|73,948|
|Debtors||443||443|
|Cash at|bank and in hand|(12,431)|98,310|85,879|
|Creditors||(2,485)||(2,485)|
|Net assets||59,459|98,326|157,585|
|Prior year|||||
|||Unrestricted|Restricted||
|||funds|funds|Total|
|Fixed assets|||||
|Tangible|fixed assets|2,854|22|2,876|
|Investments||103,333||103,333|
|||106,187|22|106,209|
|Debtors||929||929|
|Cash at|bank and in hand|(15,488)|61,131|45,643|
|Creditors||(3,662)||(3,662)|
|Net assets||87,966|61,153|149,119|
##
##